Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of short cycles of recombinant
interleukin-2 (also known as rIL-2 or aldesleukin) given with or without anti-HIV drugs in
HIV infected patients. The effects will be compared with a study group that receives no IL-2
or antiretroviral therapy.
Study hypothesis: Intermittent aldesleukin, when given without antiretroviral therapy to
patients with early HIV infection, will produce no change in HIV viral load and increases in
CD4+ T lymphocyte counts comparable to aldesleukin administered with antiretrovirals.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)